TAEK-VAC-HerBy vaccine
Term · Oncology and biomedicine · MLC-T-ONC-016959
A cancer vaccine targeting the tumor-associated antigen (TAA) HER-2/neu (ErbB-2), with potential immunomodulating and antineoplastic activities. Upon administration, TAEK-VAC-HerBy vaccine may induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing the HER-2/neu antigen, which may result in the inhibition of proliferation in Her-2/neu-expressing tumor cells. Her-2/neu, a member of the epidermal growth factor receptor (EGFR) family of tyrosine kinases, is overexpressed in various tumor cell types.
| Identifier | MLC-T-ONC-016959 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | TAEK-VAC-HerBy |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-016959",
"term": "TAEK-VAC-HerBy vaccine",
"field": "Oncology and biomedicine",
"definition": "A cancer vaccine targeting the tumor-associated antigen (TAA) HER-2/neu (ErbB-2), with potential immunomodulating and antineoplastic activities. Upon administration, TAEK-VAC-HerBy vaccine may induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing the HER-2/neu antigen, which may result in the inhibition of proliferation in Her-2/neu-expressing tumor cells. Her-2/neu, a member of the epidermal growth factor receptor (EGFR) family of tyrosine kinases, is overexpressed in various tumor cell types.",
"synonyms": [
"TAEK-VAC-HerBy"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/taek-vac-herby-vaccine/"
}
Record 15,940 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.